New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
13:00 EDTITMN, SNY, RHHBYInterMune received takeover bids from Sanofi, Roche, Bloomberg says
News For ITMN;SNY;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
05:40 EDTSNYSanofi reports Q3 business EPS EUR 1.47 vs. EUR 1.36 last year
Subscribe for More Information
October 27, 2014
20:54 EDTRHHBYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:23 EDTSNYAmerican College of Surgeons holds a conference
Subscribe for More Information
07:21 EDTSNYSanofi board explains CEO development not included in meeting, Reuters says
Subscribe for More Information
07:20 EDTRHHBYAmerican Association of Blood Banks to hold annual meeting
Subscribe for More Information
October 24, 2014
12:03 EDTRHHBYRoche reports CHMP recommends label update for Esbriet
Subscribe for More Information
October 22, 2014
07:35 EDTSNYCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTSNYFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:44 EDTSNYActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
10:37 EDTSNYSanofi unit announces Aubagio gains FDA approval due to study data
Genzyme, a Sanofi company, announced that the Food and Drug Administration has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the productís U.S. label. In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo. The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack. In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published in The Lancet Neurology in September.
08:06 EDTSNYMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:19 EDTRHHBY, SNYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBY, SNYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
07:02 EDTSNYRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
09:06 EDTSNYAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use